HEALTHWAY MEDICAL CORPORATION LIMITED
(Company Registration No. 200708625C)
(Incorporated in the Republic of Singapore)

CHANGES IN THE COMPOSITION OF THE BOARD AND BOARD COMMITTEES

The Board of Directors (the "**Board**") of Healthway Medical Corporation Limited (the "**Company**") wishes to announce the following changes at the conclusion of the shareholders' meetings held on 26 April 2019:

I. APPOINTMENT OF MR SIN BOON ANN AS INDEPENDENT NON-EXECUTIVE CHAIRMAN AND MEMBER OF EACH OF THE AUDIT AND RISK COMMITTEE, THE NOMINATING COMMITTEE AND THE REMUNERATION COMMITTEE

Mr Sin Boon Ann has been appointed as Independent Non-Executive Chairman and a member of the Audit and Risk Committee, the Nominating Committee and the Remuneration Committee. Mr Sin is considered by the Board to be independent for the purposes of Rule 704(7) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited ("**Catalist Rules**").

The announcement on the appointment of Mr Sin as an Independent Non-Executive Chairman of the Company as required under Rule 704(6) of the Catalist Rules is contained in separate announcement made today.

II. APPOINTMENT OF MR ABRAM MELKYZEDECK SUHARDIMAN AS EXECUTIVE DIRECTOR

Mr Abram Melkyzedeck Suhardiman has been appointed as an Executive Director of the Company. He will also continue to assume his role as a Chief Operating Officer of the Group.

The announcement on the appointment of Mr Suhardiman as an Executive Director of the Company as required under Rule 704(6) of the Catalist Rules is contained in separate announcement made today.

III. RETIREMENT OF MR LEE LUEN-WAI, JOHN AND MR SONNY YUEN CHEE CHOONG AS DIRECTORS OF THE COMPANY

Mr Lee Luen-Wai, John and Mr Sonny Yuen Chee Choong have retired as the Non-Independent Non-Executive Chairman and Independent Non-Executive Director of the Company.

Mr Sonny Yuen also ceased to act as the member of each of the Audit and Risk Committee, the Nominating Committee and the Remuneration Committee of the Company.

The announcements on the cessation of Mr John Lee and Mr Sonny Yuen as required under Rule 704(6) of the Catalist Rules are contained in separate announcements made today.

IV. RECONSTITUTION OF THE BOARD AND THE BOARD COMMITTEES

In light of the above changes, the composition of the Board and relevant Board Committees shall be reconstituted with immediate effect as follows:-

Board of Directors

Mr Sin Boon Ann (Independent Non-Executive Chairman)
Dr Stephen Riady (Non-Independent Non-Executive Director)
Mr Anand Kumar (Non-Independent Non-Executive Director)
Mr Chen Yeow Sin (Lead Independent Director)
Mr Lin Weiwen, Moses (Independent Non-Executive Director)
Mr Abram Melkyzedeck Suhardiman (Executive Director)

Audit and Risk Committee

Mr Chen Yeow Sin, Chairman
Mr Lin Weiwen, Moses, Member
Mr Sin Boon Ann, Member

Nominating Committee

Mr Chen Yeow Sin, Chairman
Mr Lin Weiwen, Moses, Member
Mr Sin Boon Ann, Member

Remuneration Committee

Mr Lin Weiwen, Moses, Chairman
Mr Chen Yeow Sin, Member
Mr Sin Boon Ann, Member

BY ORDER OF THE BOARD

Raymond Lam Kuo Wei
Company Secretary

26 April 2019

*This announcement has been prepared by the Company and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGXST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).